| Literature DB >> 24300451 |
Esther T L Lau1, Steven J Giddings, Salmaan G Mohammed, Paul Dubois, Stuart K Johnson, Roger A Stanley, Peter J Halley, Kathryn J Steadman.
Abstract
Zein was investigated for use as an oral-drug delivery system by loading prednisolone into zein microparticles using coacervation. To investigate the adaptability of this method to other drugs, zein microparticles were loaded with hydrocortisone, which is structurally related to prednisolone; or mesalazine, which is structurally different having a smaller LogP and ionizable functional groups. Investigations into the in vitro digestibility, and the electrophoretic profile of zein, and zein microparticles were conducted to shed further insight on using this protein as a drug delivery system. Hydrocortisone loading into zein microparticles was comparable with that reported for prednisolone, but mesalazine loading was highly variable. Depending on the starting quantities of hydrocortisone and zein, the average amount of microparticles equivalent to 4 mg hydrocortisone, (a clinically used dose), ranged from 60-115 mg, which is realistic and practical for oral dosing. Comparatively, an average of 2.5 g of microparticles was required to deliver 250 mg of mesalazine (a clinically used dose), so alternate encapsulation methods that can produce higher and more precise mesalazine loading are required. In vitro protein digestibility revealed that zein microparticles were more resistant to digestion compared to the zein raw material, and that individual zein peptides are not preferentially coacervated into the microparticles. In combination, these results suggest that there is potential to formulate a delivery system based on zein microparticles made using specific subunits of zein that is more resistant to digestion as starting material, to deliver drugs to the lower gastrointestinal tract.Entities:
Year: 2013 PMID: 24300451 PMCID: PMC3834950 DOI: 10.3390/pharmaceutics5020277
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1UV absorbance spectra (200–500 nm) of zein (0.5 mg/mL), hydrocortisone (51 µg/mL), and a mixture of zein (0.5 mg/mL) with hydrocortisone (51 µg/mL) in 70% (v/v) ethanol.
Mesalazine solubility (mg/mL) in different solvents at varying pH and temperature.
| Solvent | pH | Temperature (°C) | Solubility (mg/mL) |
|---|---|---|---|
| 70% (
| 6.5 | 25 | 0.81 |
| 70% (
| 6.5 | 37 | 1.40 |
| 70% (
| 4.5 | 25 | 0.81 |
| 0.01 M HCl | 2 | 25 | 0.89 |
| 0.1 M HCl | 1 | 25 | 1.50 |
| Distilled water | 6.5 | 25 | 0.80 |
Figure 2UV absorbance spectra (200–500 nm) of zein (0.5 mg/mL), mesalazine (51 µg/mL), and a mixture of zein (0.5 mg/mL) with mesalazine (51 µg/mL) in 70% (v/v) ethanol.
Drug loading and loading efficiency (mean ± SEM) into zein microparticles formulated using various combinations of zein and hydrocortisone, with the coefficient of variation (%CV) for within and between replicates. One-way factorial ANOVA with a post hoc Bonferroni multiple comparisons test was used to compare selected means (p < 0.05).
| Zein (mg) | Drug (mg) | Ratio | %CV | Total mean ± SEM | Total %CV | ||
|---|---|---|---|---|---|---|---|
| Rep 1 | Rep 2 | Rep 3 | |||||
|
| |||||||
| 800 | 200 | 4 | 7.71 | 15.43 | 3.01 | 5.41 ± 0.60
| 19 |
| 600 | 150 | 4 | 7.41 | 2.97 | 1.90 | 4.72 ± 0.05
| 2 |
| 200 | 50 | 4 | 5.66 | 3.98 | 21.67 | 2.84 ± 0.25
| 16 |
| 400 | 200 | 2 | 1.07 | 7.36 | 6.37 | 2.69 ± 0.08
| 5 |
| 400 | 150 | 2.7 | 5.25 | 4.87 | 7.98 | 3.68 ± 0.86
| 40 |
| 400 | 100 | 4 | 10.11 | 1.95 | 9.44 | 3.31 ± 0.20
| 11 |
| 400 | 50 | 8 | 3.11 | 8.16 | 8.49 | 3.66 ± 0.28
| 13 |
| 400 | 25 | 16 | 2.18 | 25.09 | 11.25 | 3.77 ± 0.44
| 20 |
|
| |||||||
| 800 | 200 | 4 | 6.66 | 12.64 | 3.42 | 33.13 ± 4.55
| 24 |
| 600 | 150 | 4 | 4.28 | 2.80 | 2.38 | 27.47 ± 2.28
| 14 |
| 200 | 50 | 4 | 8.31 | 1.56 | 27.00 | 16.03 ± 1.38
| 15 |
| 400 | 200 | 2 | 4.40 | 10.47 | 11.18 | 9.44 ± 0.17
| 3 |
| 400 | 150 | 2.7 | 5.53 | 1.48 | 19.01 | 14.54 ± 2.63
| 31 |
| 400 | 100 | 4 | 26.98 | 7.51 | 19.66 | 20.66 ± 0.39
| 3 |
| 400 | 50 | 8 | 5.16 | 6.05 | 4.27 | 40.55 ± 1.64
| 7 |
| 400 | 25 | 16 | 1.98 | 3.78 | 1.27 | 84.18 ± 2.40
| 5 |
Means were grouped as follows for statistical analysis, with the means that were not significantly different at p < 0.05 assigned the same letter: varying quantities with constant ratio of zein and hydrocortisone (a–b, A–B), constant quantity of zein with varying hydrocortisone quantity (x, X–Z).
Figure 3The amount of zein-hydrocortisone microparticles (mean ± SEM; n = 3) equivalent to a clinically used dose of hydrocortisone (4 mg) for samples prepared using various combinations of hydrocortisone (25–200 mg) and zein (200–800 mg). One-way factorial ANOVA with a post hoc Bonferroni test was used to compare selected means for varying quantities with constant ratio of zein and mesalazine (a–b), and a constant quantity of zein with varying mesalazine quantity (x). The level of significance was set at p < 0.05 and means that were not significantly different were assigned the same letter.
The molecular structure, pKa, LogP, aqueous solubility, and solubility in ethanol of prednisolone, hydrocortisone and mesalazine.
| Prednisolone | Hydrocortisone | Mesalazine | |
|---|---|---|---|
| Molecular structure |
|
|
|
| pKa | - | - | 2.15, 7.10, 12.30 [ |
| Log P | 1.62 [ | 1.61 [ | 0.64 [ |
| Aqueous solubility at 25 °C | 0.273 mg/mL [ | 0.311 mg/mL [ | 1.85 mg/mL [ |
| Solubility in absolute ethanol | 24.3 mg/mL at 25 °C [ | 14.7 mg/mL at 25 °C [ | 0.324 mg/mL at 24 °C [ |
Drug loading and loading efficiency (mean ± SEM) into zein microparticles formulated using various combinations of zein and mesalazine, with the coefficient of variation (%CV) for within and between replicates. One-way factorial ANOVA with a post hoc Bonferroni multiple comparisons test was used to compare selected means (p < 0.05).
| Zein (mg) | Drug (mg) | Ratio | %CV | Total mean ± SEM | Total %CV | ||
|---|---|---|---|---|---|---|---|
| Rep 1 | Rep 2 | Rep 3 | |||||
|
| |||||||
| 800 | 200 | 4 | 6.79 | 14.67 | 10.02 | 4.84 ± 3.38
| 121 |
| 600 | 150 | 4 | 8.61 | 26.28 | 4.21 | 4.66 ± 2.34
| 87 |
| 200 | 50 | 4 | 5.98 | 13.9 | 42.02 | 4.09 ± 1.54
| 65 |
| 400 | 200 | 2 | 19.05 | 5.91 | 1.57 | 8.02 ± 1.87
| 41 |
| 400 | 150 | 2.7 | 12.18 | 7.69 | 11.04 | 9.70 ± 2.84
| 51 |
| 400 | 100 | 4 | 1.58 | 4.25 | 2.41 | 2.91 ± 0.98
| 59 |
| 400 | 50 | 8 | 5.90 | 28.59 | 19.78 | 2.21 ± 0.77
| 60 |
| 400 | 25 | 16 | 17.96 | ND | ND | 0.14 ± 0.14
| ND |
|
| |||||||
| 800 | 200 | 4 | 7.60 | 12.78 | 3.38 | 33.65 ± 15.90
| 82 |
| 600 | 150 | 4 | 11.39 | 19.19 | 11.90 | 23.37 ± 13.33
| 99 |
| 200 | 50 | 4 | 4.77 | 12.80 | 37.06 | 24.71 ± 4.23
| 30 |
| 400 | 200 | 2 | 8.08 | 3.02 | 3.19 | 40.08 ± 4.77
| 21 |
| 400 | 150 | 2.7 | 6.00 | 4.31 | 8.59 | 61.69 ± 9.61
| 27 |
| 400 | 100 | 4 | 2.74 | 12.66 | 22.48 | 20.97 ± 4.75
| 39 |
| 400 | 50 | 8 | 2.12 | 28.00 | 11.20 | 21.57 ± 7.79
| 63 |
| 400 | 25 | 16 | 15.49 | ND | ND | 2.73 ± 2.73
| ND |
Means were grouped as follows for statistical analysis, with the means that were not significantly different at p < 0.05 assigned the same letter: varying quantities with constant ratio of zein and mesalazine (a, A), constant quantity of zein with varying mesalazine quantity (x, X–Y). ND: %CV could not be calculated as no mesalazine loading was observed.
Figure 4The amount of zein-mesalazine microparticles (mean ± SEM; n = 3) equivalent to a clinically used dose of mesalazine (250 mg) for samples prepared using various combinations of mesalazine (25–200 mg) and zein (200–800 mg). One-way factorial ANOVA with a post hoc Bonferroni test was used to compare selected means (varying quantities with constant ratio of zein and mesalazine, and a constant quantity of zein with varying mesalazine quantity). The means were not significantly different at p < 0.05.
Protein content and in vitro protein digestibility of zein and empty zein microparticles. Values are mean ± standard deviation (n = 3). Means within a column that were not significantly different at p < 0.05 were assigned the same letter: protein content (A,B), and in vitro protein digestibility (a,b).
| Sample | Protein content (g/100 g) | |
|---|---|---|
| Zein (raw material) | 85.4 ± 0.4 | 93.3 ± 2.2 |
| Zein microparticles (empty) | 82.9 ± 1.0 | 50.3 ± 5.8 |
Figure 5SDS-PAGE of zein and empty zein microparticles extracted with borate buffer under reducing conditions. (1) MW standards; (2), (3) zein; (4), (5) empty zein microparticles. Clear arrow, and solid arrow are peptides c. 20 kDa; solid diamond are peptides c. 40 kDa.